Panadol liquid production: Haleon to pump in £3.58m for modernisation, expansion

KARACHI: Haleon Pakistan Limited has approved a £3.58 million, approximately Rs1.25 billion, capital investment to modernize and expand its Panadol Liquid manufacturing operations, the company disclosed to the Pakistan Stock Exchange on Tuesday.

The investment, approved by the company’s Board of Directors, is aimed at addressing sustained demand for liquid and pediatric analgesics in the local market, where supply disruptions have periodically affected the availability of essential medicines.

According to the notice the funds will be deployed to upgrade production capacity for Panadol Liquid, including syrups and drops commonly used by children and patients unable to take tablets.

The expansion will focus on three key areas including installation of advanced, high-speed packaging machinery, infrastructure upgrades to support higher production volumes and compliance with global health standards and enhanced quality control systems, including improved monitoring and testing protocols.

Company officials said the investment is expected to improve operational efficiency, reduce manual handling, and increase output, particularly during periods of heightened demand such as seasonal flu outbreaks.

The move comes at a time when Pakistan’s pharmaceutical sector faces challenges related to pricing controls, supply chain pressures, and rising production costs. Analysts say Haleon’s capital commitment signals long-term confidence in the local healthcare market and may help stabilize supplies of one of the country’s most widely used over-the-counter medicines.

Haleon Pakistan is a subsidiary of UK-based Haleon plc, which was spun off from GlaxoSmithKline’s consumer healthcare business.

The company has previously invested in expanding and upgrading its Jamshoro manufacturing facility and remains one of the leading players in Pakistan’s OTC healthcare segment.

Copyright Business Recorder, 2026